Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Cash from Operations (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Cash from Operations for 6 consecutive years, with 20792000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 41.38% to 20792000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 110992000.0 through Dec 2025, up 19.69% year-over-year, with the annual reading at 110992000.0 for FY2025, 19.69% up from the prior year.
  • Cash from Operations for Q4 2025 was 20792000.0 at Caribou Biosciences, up from 25217000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 20313000.0 in Q1 2021, with the low at 37203000.0 in Q1 2024.
  • Average Cash from Operations over 5 years is 23298400.0, with a median of 23710000.0 recorded in 2022.
  • The sharpest move saw Cash from Operations tumbled 206.7% in 2022, then skyrocketed 41.38% in 2025.
  • Over 5 years, Cash from Operations stood at 21389000.0 in 2021, then fell by 17.09% to 25044000.0 in 2022, then grew by 14.63% to 21379000.0 in 2023, then crashed by 65.91% to 35470000.0 in 2024, then surged by 41.38% to 20792000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 20792000.0, 25217000.0, and 28258000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.